Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam besylate vs propofol for sedation adverse events in painless bronchoscopy
ChiCTR2500099355Phase 4Not yet recruiting
- Sponsor
- Chongqing Public health medical treatment Center
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of remimazolam and propofol (3 arms), sponsored by Chongqing Public health medical treatment Center. Primary endpoints: Pulse oxygen saturation (SpO2), Feasibility of diagnosis and treatment procedures (vocal cord movement, coughing, body movement) and 1 more. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
remimazolampropofol
Beyond the preview
Go deeper on ChiCTR2500099355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500099355.